AdAlta Limited (ASX:1AD)
Australia · Delayed Price · Currency is AUD 0.0030
0.00 (0.00%)
Sep 18, 2026, 3:08 PM AEST
AdAlta Revenue
In the fiscal year ending June 30, 2026, AdAlta had annual revenue of 404.25K AUD, down -40.29%. AdAlta had revenue of 98.10K in the half year ending June 30, 2026, a decrease of -83.59%.
Revenue
404.25K
Revenue Growth
-40.29%
P/S Ratio
23.84
Revenue / Employee
202.12K
Employees
2
Market Cap
9.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 404.25K | -272.77K | -40.29% |
| Jun 30, 2025 | 677.01K | -1.06M | -61.04% |
| Jun 30, 2024 | 1.74M | -1.73M | -49.91% |
| Jun 30, 2023 | 3.47M | 715.56K | 25.99% |
| Jun 30, 2022 | 2.75M | -1.23M | -30.89% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.71M |
| Acrux | 6.58M |
| Neurotech International | 4.73M |
| Vectus Biosystems | 2.77M |
| Cambium Bio | 1.23M |
| Bio-Gene Technology | 1.08M |
| Biotron | 525.87K |
| ReNerve | 510.36K |
AdAlta News
- 4 weeks ago - AdAlta Annual report: H2 2026 - Filings
- 5 weeks ago - AdAlta Slides: Investor presentation - Filings
- 2 months ago - AdAlta Slides: Investor presentation - Filings
- 4 months ago - AdAlta Transcript: Investor update - Transcripts
- 4 months ago - AdAlta Slides: Investor update - Filings
- 4 months ago - AdAlta Earnings release: Q3 2026 - Filings
- 7 months ago - AdAlta Quarterly report: H1 2026 - Filings
- 7 months ago - AdAlta Slides: Investor presentation - Filings